NFKB1 and cancer: Given that the insurmountable challenge with conventional NF-κB or IKKβ inhibitors has been to achieve cancer-cell specificity, due to the pleiotropic and ubiquitous functions of NF-κB [11], agents targeting these effectors, having functional restriction to cancer cells or their microenvironment, could provide safer and more selective anticancer therapeutics, lacking the dose-limiting toxicities of global NF-κB inhibitors.